Literature DB >> 33739254

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.

Daniel J Grint1, Kevin Wing1, Elizabeth Williamson1, Helen I McDonald1, Krishnan Bhaskaran1, David Evans2, Stephen Jw Evans1, Alex J Walker2, George Hickman2, Emily Nightingale3, Anna Schultze1, Christopher T Rentsch1, Chris Bates4, Jonathan Cockburn4, Helen J Curtis2, Caroline E Morton2, Sebastian Bacon2, Simon Davy2, Angel Ys Wong1, Amir Mehrkar2, Laurie Tomlinson1, Ian J Douglas1, Rohini Mathur1, Paula Blomquist5, Brian MacKenna2, Peter Ingelsby2, Richard Croker2, John Parry4, Frank Hester4, Sam Harper4, Nicholas J DeVito2, Will Hulme2, John Tazare1, Ben Goldacre2,6, Liam Smeeth1,6, Rosalind M Eggo1,6.   

Abstract

The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (hazard ratio: 1.67; 95% confidence interval: 1.34-2.09; p < 0.0001). Absolute risk of death by 28 days increased with age and comorbidities. This VOC has potential to spread faster with higher mortality than the pandemic to date.

Entities:  

Keywords:  CFR; COVID-19; Case fatality risk; Coronavirus; Mortality; SARS-CoV-2; Variant of concern

Mesh:

Year:  2021        PMID: 33739254      PMCID: PMC7976383          DOI: 10.2807/1560-7917.ES.2021.26.11.2100256

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  5 in total

1.  Covid-19: New UK variant may be linked to increased death rate, early data indicate.

Authors:  Gareth Iacobucci
Journal:  BMJ       Date:  2021-01-26

2.  UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records.

Authors:  Jemma L Walker; Daniel J Grint; Helen Strongman; Rosalind M Eggo; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T Rentsch; Ian J Douglas; Rohini Mathur; Angel Y S Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald
Journal:  BMC Public Health       Date:  2021-03-11       Impact factor: 4.135

3.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.

Authors:  Sam Abbott; Rosanna C Barnard; Christopher I Jarvis; Adam J Kucharski; James D Munday; Carl A B Pearson; Timothy W Russell; Damien C Tully; Alex D Washburne; Tom Wenseleers; Nicholas G Davies; Amy Gimma; William Waites; Kerry L M Wong; Kevin van Zandvoort; Justin D Silverman; Karla Diaz-Ordaz; Ruth Keogh; Rosalind M Eggo; Sebastian Funk; Mark Jit; Katherine E Atkins; W John Edmunds
Journal:  Science       Date:  2021-03-03       Impact factor: 63.714

4.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.

Authors:  Karla Diaz-Ordaz; Ruth H Keogh; Nicholas G Davies; Christopher I Jarvis; W John Edmunds; Nicholas P Jewell
Journal:  Nature       Date:  2021-03-15       Impact factor: 69.504

5.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.

Authors:  Robert Challen; Ellen Brooks-Pollock; Jonathan M Read; Louise Dyson; Krasimira Tsaneva-Atanasova; Leon Danon
Journal:  BMJ       Date:  2021-03-09
  5 in total
  62 in total

1.  Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.

Authors:  Ralf Duerr; Dacia Dimartino; Christian Marier; Paul Zappile; Guiqing Wang; Jennifer Lighter; Brian Elbel; Andrea B Troxel; Adriana Heguy
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

2.  Initial Proportion and Dynamic of B.1.1.7 SARS-CoV-2 in a Large City in the West of Germany.

Authors:  Simon D Herkenrath; Kyrill Boschung; Julia A Nacov; Annette Heibges; Britta Schroer; Marcel Treml; Winfried J Randerath
Journal:  Biomed Hub       Date:  2022-02-25

3.  Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK.

Authors:  Chia Siang Kow; Hamid A Merchant; Syed Shahzad Hasan
Journal:  J Infect       Date:  2021-05-13       Impact factor: 6.072

4.  Severe Acute Respiratory Syndrome Coronavirus 2: The Emergence of Important Genetic Variants and Testing Options for Clinical Laboratories.

Authors:  Blake W Buchan; Joseph D Yao
Journal:  Clin Microbiol Newsl       Date:  2021-05-21

5.  The surge in Covid related mucormycosis.

Authors:  Somesh Chandra; Rakesh Rawal
Journal:  J Infect       Date:  2021-06-12       Impact factor: 38.637

Review 6.  The Emerging Concern and Interest SARS-CoV-2 Variants.

Authors:  Edyta Janik; Marcin Niemcewicz; Marcin Podogrocki; Ireneusz Majsterek; Michal Bijak
Journal:  Pathogens       Date:  2021-05-21

7.  SARS-CoV-2 variants and considerations of inferring causality on disease severity.

Authors:  Muge Cevik; Sharmistha Mishra
Journal:  Lancet Infect Dis       Date:  2021-06-22       Impact factor: 25.071

8.  Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.

Authors:  Martina Patone; Karen Thomas; Rob Hatch; Pui San Tan; Carol Coupland; Weiqi Liao; Paul Mouncey; David Harrison; Kathryn Rowan; Peter Horby; Peter Watkinson; Julia Hippisley-Cox
Journal:  Lancet Infect Dis       Date:  2021-06-22       Impact factor: 25.071

Review 9.  Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19).

Authors:  Ting Wu; Shuntong Kang; Wenyao Peng; Chenzhe Zuo; Yuhao Zhu; Liangyu Pan; Keyun Fu; Yaxian You; Xinyuan Yang; Xuan Luo; Liping Jiang; Meichun Deng
Journal:  Front Med (Lausanne)       Date:  2021-07-06

10.  Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis.

Authors:  Tommy Nyberg; Katherine A Twohig; Ross J Harris; Shaun R Seaman; Joe Flannagan; Hester Allen; Andre Charlett; Daniela De Angelis; Gavin Dabrera; Anne M Presanis
Journal:  BMJ       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.